A PYMNTS Company

Canada: Allergan to buy Merck Migraine candidates for $250 million

By  |  July 7, 2015

Allergan and Merck announced that they have entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck’s investigational small molecule that is being developed for the treatment and prevention of migraine.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Under the terms of the agreement, Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance.

    Merck said the deal will allow it to focus on priority therapeutic areas—which the company has identified as being oncology, diabetes, acute hospital care, and vaccines.

    Full content: GEN

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.